RedHill Biopharma Announces Last Patient Randomized in Part A ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TEL AVIV, Israel and RALEIGH, N.C., Nov. 15, 2021 /PRNewswire-AsiaNet/ -- - Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care- Top-line results for Part A of the study, designed to eval...
Authors: LATEST ASIANET NEWS RELEASES